Cancer Network Staff

Blinded survival data from the phase 3 LIVERATION trial of namodenoson in advanced hepatocellular carcinoma appear longer than anticipated.

According to Margarita Racsa, MD, MPH, patients coming in with AI-informed insights can be a double-edged sword for clinicians.

Patients with nonmetastatic prostate cancer in the highest quintile of postdiagnosis saturated fat consumption showed a 24% greater risk of all-cause mortality vs the lowest quintile.

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.

The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09.

Updated HERIZON-GEA-01 survival data show zanidatamab-based regimens outperformed trastuzumab/chemotherapy in first-line HER2-positive advanced GEA.

The regulatory decision for JBS-003 is intended to help guide personalized radiation de-escalation in patients with HPV-positive oropharyngeal cancer.

AI is intended to assist physicians, giving them more time for interpersonal engagement with patients, according to Nevine Hanna, MD, MPH, FACRO, DABR.

Updated interim PYNNACLE trial data showed a 46% response rate with rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer.

Tumor-informed ctDNA testing with the Signatera assay outperformed standard PET/CT imaging across B- and T-cell lymphoma subtypes.

Data from the phase 3 SENTRY trial support the supplemental new drug application for selinexor plus ruxolitinib in patients with myelofibrosis.

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.

Final COMBI-I data show a survival advantage with spartalizumab plus dabrafenib/trametinib over dabrafenib/trametinib alone in BRAF V600-mutant melanoma.

Savolitinib/osimertinib significantly improved progression-free survival vs osimertinib alone as first-line treatment in the phase 3 SANOVO trial.

BioNTech has terminated a phase 2 trial of autogene cevumeran in ctDNA-positive, resected colorectal cancer after a DSMB found an overall survival imbalance.

ASCO’s first living guideline for recurrent ovarian cancer recommends platinum-based doublets, selective bevacizumab, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease.

The FDA granted fast track designation to the ADC SOT106 for soft tissue sarcoma, with a first-in-human trial planned this year.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

ASCO has issued a critical drug supply warning as some practices report just weeks of ifosfamide inventory remaining, with no direct substitute available.

Enrollment for a phase 1 trial evaluating ADI-212, an armored allogeneic gamma delta 1 CAR T cell therapy, in metastatic CRPC is planned for Q4 2026.

Neoadjuvant botensilimab plus balstilimab produced major pathologic responses in 41% of pMMR and 100% of dMMR colorectal tumors in the phase 2 NEST trial.

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

In the final analysis of the phase 3 MAIA trial, daratumumab-based treatment yielded a median overall survival of 90.3 months in transplant-ineligible NDMM.

Final phase 1/1b data for soquelitinib in T-cell lymphoma showed a 37.5% ORR and a 28.1-month median OS in patients who received 1 to 3 prior lines of therapy.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Josef Vymazal, MD, DSc, discusses a prospective study comparing delayed single- and double-dose gadopiclenol MRI for detecting small brain metastases.

The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma based on RASolute 302 trial data.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

The FDA granted fast track designation to the pan-RAS molecular glue ERAS-0015 for metastatic pancreatic adenocarcinoma.

In a real-world setting, enfortumab vedotin plus pembrolizumab produced a 50.2% ORR among patients with metastatic/locally advanced urothelial carcinoma.